RT Journal Article
SR Electronic
T1 Implementing Precision Medicine for Dilated Cardiomyopathy: Insights from The DCM Consortium
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.22.24317816
DO 10.1101/2024.11.22.24317816
A1 Jordan, Elizabeth
A1 Ni, Hanyu
A1 Parker, Patricia
A1 Kinnamon, Daniel D.
A1 Owens, Anjali
A1 Lowes, Brian
A1 Shenoy, Chetan
A1 Martin, Cindy M.
A1 Judge, Daniel P.
A1 Fishbein, Daniel P.
A1 Stoller, Douglas
A1 Minami, Elina
A1 Kransdorf, Evan
A1 Smart, Frank
A1 Haas, Garrie J.
A1 Huggins, Gordon S.
A1 Ewald, Gregory A.
A1 Diamond, Jamie
A1 Wilcox, Jane E.
A1 Jimenez, Javier
A1 Wang, Jessica
A1 Tallaj, Jose
A1 Drazner, Mark H.
A1 Hofmeyer, Mark
A1 Wheeler, Matthew T.
A1 Wever Pinzon, Omar
A1 Shah, Palak
A1 Gottlieb, Stephen S.
A1 Katz, Stuart
A1 Shore, Supriya
A1 Tang, W. H. Wilson
A1 Hershberger, Ray E.
A1 DCM Precision Medicine study of the DCM Consortium
YR 2024
UL http://medrxiv.org/content/early/2024/11/26/2024.11.22.24317816.abstract
AB Background Clinical genetic evaluation of dilated cardiomyopathy (DCM) is implemented variably or not at all. Identifying needs and barriers to genetic evaluations will enable strategies to enhance precision medicine care.Methods An online survey was conducted in June 2024 among cardiologist investigators of the DCM Consortium from US advanced heart failure/transplant (HF/TX) programs to collect demographics, training, program characteristics, genetic evaluation practices for DCM, and implementation needs. An in-person discussion followed.Results Twenty-five cardiologists (28% female, 12% Hispanic, 68% White) participated in the survey and 15 in the discussion; genetics training backgrounds varied greatly. Clinical genetic testing for DCM was conducted by all programs with annual uptake ranging from 5%-70% (median 25%). Thirteen respondents (52%) did not use selection criteria for testing whereas others selected patients based on specific clinical and family history data. Eight (32%) ordered testing by themselves, and the remainder had testing managed mostly by a genetic counselor or others with genetic expertise (16/17; 94%). Six themes were distilled from open-ended responses regarding thoughts for the future and included access to genetics services, navigating uncertainty, knowledge needs, cost concerns, family-based care barriers, and institutional infrastructure limitations. Following an in-person discussion, four areas were identified for focused effort: improved reimbursement for genetic services, genetic counselor integration with HF/TX teams, improved provider education resources, and more research to find missing heritability and to resolve uncertain results.Conclusions HF/TX programs have implementation challenges in the provision of DCM genetic evaluations; targeted plans to facilitate precision medicine for DCM are needed.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialclinicaltrials.gov, NCT03037632Funding StatementResearch reported in this publication was supported by a parent award from the National Heart, Lung, And Blood Institute of the National Institutes of Health (NIH) under Award Number R01HL128857, which included a supplement from the National Human Genome Research Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:no specific IRB approval was required for this survey of study investigators.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData from this manuscript can be shared upon reasonable request.